Zobrazeno 1 - 10
of 15
pro vyhledávání: '"K Bahrt"'
Autor:
Michael Schiff, Xianhuang Zhou, S. Kelly, J E Huffstutter, V Rodriguez-Valverde, K Bahrt, Tracy Li, C Pritchard, Patrick Durez, Mark C. Genovese, M. Le Bars
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 68, no. 11, p. 1708-1714 (2009)
Annals of the Rheumatic Diseases, Vol. 68, no. 11, p. 1708-1714 (2009)
Objective: To assess the safety, tolerability and efficacy of abatacept in patients with rheumatoid arthritis (RA) who had failed anti-tumour necrosis factor (TNF) therapy and were switched to abatacept directly or after completing washout. Methods:
Autor:
Jose Cocco Maldonado, Richard Aranda, Rene Westhovens, J-C Becker, Y Zhou, Maxime Dougados, K Bahrt
Publikováno v:
JCR: Journal of Clinical Rheumatology. 12:S48-S49
Autor:
T L McCann, Carlos Glave, J-C Becker, C Abud, Larry W. Moreland, Michael E. Weinblatt, Richard Aranda, K Bahrt
Publikováno v:
JCR: Journal of Clinical Rheumatology. 12:S46-S47
Publikováno v:
JCR: Journal of Clinical Rheumatology. 12:S47-S48
Autor:
Carlos Abud-Mendoza, Michael E. Weinblatt, K Bahrt, Larry W. Moreland, J-C Becker, T L McCann, Richard Aranda, M Garza
Publikováno v:
JCR: Journal of Clinical Rheumatology. 12:S43-S44
Publikováno v:
Annals of the Rheumatic Diseases. 72:A703.3-A704
Background Pegloticase was recently approved in the EU for severe debilitating chronic tophaceous gout in patients refractory or with intolerance to xanthine oxidase inhibitors. The pegloticase development program included 2 replicate randomized, pla
Publikováno v:
Annals of the Rheumatic Diseases. 71:699.9-699
Background Pegloticase was approved for the treatment of refractory chronic gout in the U.S. in 2010. The pegloticase registration program comprised 2, 6-month placebo-controlled Phase 3 trials (RCTs) followed by an open-label (OL) safety study for a
Publikováno v:
Annals of the Rheumatic Diseases. 72:A711.1-A711
Background Pegloticase is a recombinant uricase recently approved in the EU for the treatment of severe, debilitating chronic tophaceous gout refractory to xanthine oxidase inhibitors (XOIs) or when XOIs are contraindicated. The pegloticase program i
Publikováno v:
JCR: Journal of Clinical Rheumatology. 12:S51
Autor:
K Bahrt, J-C Becker, M Garza, T L McCann, Richard Aranda, Larry W. Moreland, Carlos Glave, Michael E. Weinblatt
Publikováno v:
JCR: Journal of Clinical Rheumatology. 12:S46